Sugi Predict

Sugi Predict / Compounds / SCHEMBL2937098

SCHEMBL2937098

SCHEMBL2937098

COc1ccc(-c2cnccc2CN2C(=O)N(c3ccc(S(=O)(=O)C(F)(F)F)cc3)C(=O)C2C)cc1

nearest known ligand 0.59

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ IGF1R P08069 2/20 0.59
▸ SLC22A12 Q96S37 1/20 0.42
▸ CACNA1B Q00975 1/20 0.37
▸ CYP11B1 P15538 2/20 0.36
▸ CYP11B2 P19099 2/20 0.36
▸ MAPT P10636 1/20 0.35
▸ TP53 P04637 1/20 0.35
▸ SMO Q99835 2/20 0.34
▸ PTGS2 P35354 5/20 0.33
▸ PTGS1 P23219 3/20 0.33
▸ TSHR P16473 1/20 0.33
▸ CTSS P25774 1/20 0.33
▸ POLB P06746 1/20 0.33
▸ MAPK1 P28482 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2937511 0.91 IGF1R (0.61) IGF1RSLC22A12CACNA1BSMOPTGS2
SCHEMBL2932237 0.90 IGF1R (0.60) IGF1RCACNA1BSMOCTSS
SCHEMBL2938023 0.90 IGF1R (0.67) IGF1RCACNA1BSMOPTGS2PTGS1
SCHEMBL2940994 0.88 IGF1R (0.43) IGF1RSLC22A12CACNA1BCYP11B1CYP11B2
SCHEMBL2934730 0.87 IGF1R (0.65) IGF1RSLC22A12SMOPTGS2PTGS1
SCHEMBL2939789 0.85 IGF1R (0.41) IGF1RSLC22A12CACNA1BCYP11B1CYP11B2
SCHEMBL2939656 0.83 IGF1R (0.59) IGF1RCYP11B1CYP11B2SMOPTGS2
SCHEMBL2939128 0.83 IGF1R (0.53) IGF1RMAPTTP53POLB
SCHEMBL2939259 0.83 IGF1R (0.68) IGF1RSMOCTSSMAPK1
SCHEMBL2932195 0.83 IGF1R (0.67) IGF1RSMOCTSSMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7825115-B2 Cyclic urea compounds, preparation thereof and pharmaceutical use thereof as kinase inhibitors AVENTIS PHARMA S.A. (FR) 2010-11-02 — — US disclosed
EP-1599464-B1 NOVEL CYCLIC UREA DERIVATIVES, PREPARATION METHOD THEREOF AND PHARMACEUTICAL USE OF SAME AS KINASE INHIBITORS AVENTIS PHARMA SA (FR) 2010-09-22 — — EP disclosed
US-20080108654-A1 Cyclic Urea Compounds, Preparation Thereof and Pharmaceutical Use Thereof as Kinase Inhibitors AVENTIS PHARMA S.A. (FR) 2008-05-08 — — US disclosed
US-7354933-B2 Protein kinase inhibitors; antitumor agents; such as 5-methyl-1-quinol-4-ylmethyl-3-(4-trifluoromethanesulfonylphenyl)imidazolidine-2,4-dione trifluoroacetate AVENTIS PHARMA SA (FR) 2008-04-08 — — US disclosed
US-20040248884-A1 Novel cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors AVENTIS PHARMA S.A. (FR) 2004-12-09 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080108654-A1 Cyclic Urea Compounds, Preparation Thereof and Pharmaceutical Use Thereof as Kinase Inhibitors PRKG1, PRKACA, CMPK1 IGF1R 1595/4885SLC22A12 3963/4885CACNA1B 4752/4885
US-20040248884-A1 Novel cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors PRKG1, PRKACA, PRKCA IGF1R 962/4885SLC22A12 3835/4885CACNA1B 4689/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.